Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the<i>F508del-CFTR</i>mutation
収録刊行物
-
- Thorax
-
Thorax 67 (1), 12-18, 2011-08-08
BMJ